Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen announces positive results of pivotal denosumab study

Amgen announces positive results of pivotal denosumab study

10th February 2010

Amgen announced this week that a pivotal phase III trial evaluating denosumab against a traditional therapy in the treatment of bone metastases in men with advanced prostate cancer met both its primary and secondary endpoints.

Denosumab demonstrated superiority over the existing treatment for both delaying the time to the first skeletal-related event (SRE) – such as fracture, radiation to bone, surgery to bone or spinal cord compression – and reducing the occurrence of multiple SREs.

In particular, osteonecrosis of the jaw was infrequent and both overall survival and the time to cancer progression were found to be balanced between treatment arms.

Roger Perlmutter, executive vice-president of research and development at Amgen, said: “Denosumab has shown remarkable consistency in reducing the serious complications of bone metastases. Today’s results greatly enhance our understanding of the efficacy of denosumab in multiple different tumour types.”

Last month, Amgen posted its financial results for the final quarter of 2009, revealing a revenue increase of two per cent for the period.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.